September 30, 2020
JCR Pharmaceuticals said on September 29 that it has submitted a new drug application in Japan for its investigational iduronate-2-sulfatase agent pabinafusp alfa (JR-141) for the treatment of Hunter syndrome. JR-141, which is developed by using the company’s blood-brain-barrier (BBB)...read more